People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bayhill Therapeutics, Inc. | — | Pharmaceuticals | Series A | $10.0M | $309.7M | 2009 |
Paul B. Westberg at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul B. Westberg on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Rosina Maar Pavia, M.D. | 1 | 2 |
| Mark W. Schwartz | 1 | 2 |
| Philip M. Young | 1 | 2 |
| Hideki Garren | 1 | 2 |
| James N. Woody, M.D., Ph.D | 1 | 2 |
| Richard P. Powers | 1 | 2 |
| Lawrence Steinman, M.D. | 1 | 1 |
| Joanne Quan, M.D. | 1 | 1 |
| Robert S. King | 1 | 1 |
| Frederick J. Dotzler | 1 | 1 |
| David E. Thompson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.